<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2010-09-14" updated="2020-01-02">
  <drugbank-id primary="true">DB06771</drugbank-id>
  <drugbank-id>DB05862</drugbank-id>
  <name>Besifloxacin</name>
  <description>Besifloxacin is a fourth generation fluoroquinolone-type opthalmic antibiotic for the treatment of bacterial conjunctivitis. FDA approved on May 28, 2009.</description>
  <cas-number>141388-76-3</cas-number>
  <unii>BFE2NBZ7NX</unii>
  <average-mass>393.84</average-mass>
  <monoisotopic-mass>393.125547465</monoisotopic-mass>
  <state>liquid</state>
  <groups>
    <group>approved</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A7052</ref-id>
        <pubmed-id>22729919</pubmed-id>
        <citation>O'Brien TP: Besifloxacin ophthalmic suspension, 0.6%: a novel topical fluoroquinolone for bacterial conjunctivitis. Adv Ther. 2012 Jun;29(6):473-90. doi: 10.1007/s12325-012-0027-7. Epub 2012 Jun 20.</citation>
      </article>
      <article>
        <ref-id>A7053</ref-id>
        <pubmed-id>19492955</pubmed-id>
        <citation>Proksch JW, Granvil CP, Siou-Mermet R, Comstock TL, Paterno MR, Ward KW: Ocular pharmacokinetics of besifloxacin following topical administration to rabbits, monkeys, and humans. J Ocul Pharmacol Ther. 2009 Aug;25(4):335-44. doi: 10.1089/jop.2008.0116.</citation>
      </article>
    </articles>
    <textbooks/>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication>Treatment of bacterial conjunctivitis. Bacterial isolates that are susceptible to besifloxacin include: CDC coryneform group G; Corynebacterium pseudodiphtheriticum; Corynebacterium striatum; Haemophilus influenzae; Moraxella lacunata; Staphylococcus aureus; Staphylococcus epidermidis; Staphylococcus hominis; Staphylococcus lugdunensis; Streptococcus mitis group; Streptococcus oralis; Streptococcus pneumoniae; Streptococcus salivarius* </indication>
  <pharmacodynamics>Besifloxacin tear concentrations were higher than MIC90 (minimum inhibitory concentration) values for common bacterial pathogens and sustained for 24 hours or longer. Mean residence time in the conjunctiva was 4.7 hours. </pharmacodynamics>
  <mechanism-of-action>Besifloxacin is a bactericidal fluroquinolone-type antibiotic that inhibits bacterial enzymes, DNA gyrase and topoisomerase IV. By inhibiting DNA gyrase, DNA replication, transcription, and repair is impaired. By inhibiting topoisomerase IV, decatenation during cell devision is impaired. Inhibiting these two targets also slows down development of resistance. </mechanism-of-action>
  <toxicity>LD50, rat: &gt;2000 mg/kg. The most common adverse reaction reported in 2% of patients treated with besifloxacin was conjunctival redness. </toxicity>
  <metabolism>No appreciable metabolism </metabolism>
  <absorption>Although ocular surface concentrations are high, average systemic concentrtions after three-times daily dosing was less than 0.5 ng/mL. This indicates that besifloxacin is not appreciably absorbed into the systemic and has a very low risk of systemic side effects. </absorption>
  <half-life>The average elimination half-life of besifloxacin in plasma following multiple dosing was estimated to be 7 hours.</half-life>
  <protein-binding>None </protein-binding>
  <route-of-elimination>N/A </route-of-elimination>
  <volume-of-distribution>Not absorbed into the systemic </volume-of-distribution>
  <clearance>N/A</clearance>
  <classification>
    <description>This compound belongs to the class of organic compounds known as quinoline carboxylic acids. These are quinolines in which the quinoline ring system is substituted by a carboxyl group at one or more positions.</description>
    <direct-parent>Quinoline carboxylic acids</direct-parent>
    <kingdom>Organic compounds</kingdom>
    <superclass>Organoheterocyclic compounds</superclass>
    <class>Quinolines and derivatives</class>
    <subclass>Quinoline carboxylic acids</subclass>
    <alternative-parent>Amino acids</alternative-parent>
    <alternative-parent>Aminoquinolines and derivatives</alternative-parent>
    <alternative-parent>Aryl chlorides</alternative-parent>
    <alternative-parent>Aryl fluorides</alternative-parent>
    <alternative-parent>Azacyclic compounds</alternative-parent>
    <alternative-parent>Azepanes</alternative-parent>
    <alternative-parent>Benzenoids</alternative-parent>
    <alternative-parent>Carboxylic acids</alternative-parent>
    <alternative-parent>Chloroquinolines</alternative-parent>
    <alternative-parent>Dialkylarylamines</alternative-parent>
    <alternative-parent>Fluoroquinolones</alternative-parent>
    <alternative-parent>Heteroaromatic compounds</alternative-parent>
    <alternative-parent>Hydrocarbon derivatives</alternative-parent>
    <alternative-parent>Hydroquinolines</alternative-parent>
    <alternative-parent>Hydroquinolones</alternative-parent>
    <alternative-parent>Monoalkylamines</alternative-parent>
    <alternative-parent>Monocarboxylic acids and derivatives</alternative-parent>
    <alternative-parent>Organic oxides</alternative-parent>
    <alternative-parent>Organochlorides</alternative-parent>
    <alternative-parent>Organofluorides</alternative-parent>
    <alternative-parent>Organooxygen compounds</alternative-parent>
    <alternative-parent>Organopnictogen compounds</alternative-parent>
    <alternative-parent>Pyridinecarboxylic acids</alternative-parent>
    <alternative-parent>Vinylogous amides</alternative-parent>
    <substituent>Amine</substituent>
    <substituent>Amino acid</substituent>
    <substituent>Amino acid or derivatives</substituent>
    <substituent>Aminoquinoline</substituent>
    <substituent>Aromatic heteropolycyclic compound</substituent>
    <substituent>Aryl chloride</substituent>
    <substituent>Aryl fluoride</substituent>
    <substituent>Aryl halide</substituent>
    <substituent>Azacycle</substituent>
    <substituent>Azepane</substituent>
    <substituent>Benzenoid</substituent>
    <substituent>Carboxylic acid</substituent>
    <substituent>Carboxylic acid derivative</substituent>
    <substituent>Chloroquinoline</substituent>
    <substituent>Dialkylarylamine</substituent>
    <substituent>Dihydroquinoline</substituent>
    <substituent>Dihydroquinolone</substituent>
    <substituent>Fluoroquinolone</substituent>
    <substituent>Haloquinoline</substituent>
    <substituent>Heteroaromatic compound</substituent>
    <substituent>Hydrocarbon derivative</substituent>
    <substituent>Monocarboxylic acid or derivatives</substituent>
    <substituent>Organic nitrogen compound</substituent>
    <substituent>Organic oxide</substituent>
    <substituent>Organic oxygen compound</substituent>
    <substituent>Organochloride</substituent>
    <substituent>Organofluoride</substituent>
    <substituent>Organohalogen compound</substituent>
    <substituent>Organonitrogen compound</substituent>
    <substituent>Organooxygen compound</substituent>
    <substituent>Organopnictogen compound</substituent>
    <substituent>Primary aliphatic amine</substituent>
    <substituent>Primary amine</substituent>
    <substituent>Pyridine</substituent>
    <substituent>Pyridine carboxylic acid</substituent>
    <substituent>Pyridine carboxylic acid or derivatives</substituent>
    <substituent>Quinoline-3-carboxylic acid</substituent>
    <substituent>Tertiary aliphatic/aromatic amine</substituent>
    <substituent>Tertiary amine</substituent>
    <substituent>Vinylogous amide</substituent>
  </classification>
  <salts>
    <salt>
      <drugbank-id primary="true">DBSALT000018</drugbank-id>
      <name>Besifloxacin hydrochloride</name>
      <unii>7506A6J57T</unii>
      <cas-number>405165-61-9</cas-number>
      <inchikey>PMQBICKXAAKXAY-HNCPQSOCSA-N</inchikey>
      <average-mass>430.301</average-mass>
      <monoisotopic-mass>429.102225204</monoisotopic-mass>
    </salt>
  </salts>
  <synonyms>
    <synonym language="english" coder="inn">Besifloxacin</synonym>
  </synonyms>
  <products>
    <product>
      <name>Besivance</name>
      <labeller>Bausch &amp; Lomb Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02336847</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-01-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension</dosage-form>
      <strength>0.6 %</strength>
      <route>Ophthalmic</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Besivance</name>
      <labeller>Bausch &amp; Lomb Incorporated</labeller>
      <ndc-id/>
      <ndc-product-code>24208-446</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-05-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension</dosage-form>
      <strength>6 mg/1mL</strength>
      <route>Ophthalmic</route>
      <fda-application-number>NDA022308</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Besivance</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-1241</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-05-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension</dosage-form>
      <strength>6 mg/1mL</strength>
      <route>Ophthalmic</route>
      <fda-application-number>NDA022308</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Besivance</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-6282</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-07-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension</dosage-form>
      <strength>6 mg/1mL</strength>
      <route>Ophthalmic</route>
      <fda-application-number>NDA022308</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>Besivance</name>
      <ingredients>Besifloxacin</ingredients>
    </mixture>
    <mixture>
      <name>Besivance</name>
      <ingredients>Besifloxacin</ingredients>
    </mixture>
    <mixture>
      <name>Besivance</name>
      <ingredients>Besifloxacin</ingredients>
    </mixture>
    <mixture>
      <name>Besivance</name>
      <ingredients>Besifloxacin</ingredients>
    </mixture>
  </mixtures>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Anti-Bacterial Agents</category>
      <mesh-id>D000900</mesh-id>
    </category>
    <category>
      <category>Anti-Infective Agents</category>
      <mesh-id>D000890</mesh-id>
    </category>
    <category>
      <category>Antineoplastic Agents</category>
      <mesh-id>D000970</mesh-id>
    </category>
    <category>
      <category>Cytochrome P-450 CYP1A2 Inhibitors</category>
      <mesh-id>D065609</mesh-id>
    </category>
    <category>
      <category>Cytochrome P-450 CYP1A2 Inhibitors (strength unknown)</category>
      <mesh-id/>
    </category>
    <category>
      <category>Cytochrome P-450 Enzyme Inhibitors</category>
      <mesh-id>D065607</mesh-id>
    </category>
    <category>
      <category>Enzyme Inhibitors</category>
      <mesh-id>D004791</mesh-id>
    </category>
    <category>
      <category>Fluoroquinolones</category>
      <mesh-id>D024841</mesh-id>
    </category>
    <category>
      <category>Heterocyclic Compounds, Fused-Ring</category>
      <mesh-id>D000072471</mesh-id>
    </category>
    <category>
      <category>Moderate Risk QTc-Prolonging Agents</category>
      <mesh-id/>
    </category>
    <category>
      <category>Ophthalmologicals</category>
      <mesh-id/>
    </category>
    <category>
      <category>QTc Prolonging Agents</category>
      <mesh-id/>
    </category>
    <category>
      <category>Quinolines</category>
      <mesh-id>D011804</mesh-id>
    </category>
    <category>
      <category>Quinolone Antimicrobial</category>
      <mesh-id/>
    </category>
    <category>
      <category>Quinolones</category>
      <mesh-id>D015363</mesh-id>
    </category>
    <category>
      <category>Sensory Organs</category>
      <mesh-id/>
    </category>
    <category>
      <category>Topoisomerase II Inhibitors</category>
      <mesh-id>D059005</mesh-id>
    </category>
    <category>
      <category>Topoisomerase Inhibitors</category>
      <mesh-id>D059003</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Gram negative and gram positive bacteria</affected-organism>
    <affected-organism>Pseudomonas aeruginosa</affected-organism>
    <affected-organism>Streptococcus pneumoniae</affected-organism>
    <affected-organism>Haemophilus influenzae</affected-organism>
    <affected-organism>Staphylococcus aureus</affected-organism>
    <affected-organism>Aerococcus viridans</affected-organism>
    <affected-organism>Corynebacterium sp. G</affected-organism>
    <affected-organism>Corynebacterium pseudodiphtheriticum</affected-organism>
    <affected-organism>Corynebacterium striatum</affected-organism>
    <affected-organism>Moraxella catarrhalis</affected-organism>
    <affected-organism>Moraxella lacunata</affected-organism>
    <affected-organism>Staphylococcus epidermidis</affected-organism>
    <affected-organism>Staphylococcus hominis</affected-organism>
    <affected-organism>Staphylococcus lugdunensis</affected-organism>
    <affected-organism>Staphylococcus warneri</affected-organism>
    <affected-organism>Streptococcus mitis</affected-organism>
    <affected-organism>Streptococcus oralis</affected-organism>
    <affected-organism>Streptococcus salivarius</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Suspension</form>
      <route>Ophthalmic</route>
      <strength>0.6 %</strength>
    </dosage>
    <dosage>
      <form>Suspension</form>
      <route>Ophthalmic</route>
      <strength>6 mg/1mL</strength>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="S01AE08">
      <level code="S01AE">Fluoroquinolones</level>
      <level code="S01A">ANTIINFECTIVES</level>
      <level code="S01">OPHTHALMOLOGICALS</level>
      <level code="S">SENSORY ORGANS</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes>
    <ahfs-code>52:04.04</ahfs-code>
  </ahfs-codes>
  <pdb-entries/>
  <fda-label>//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB06771.pdf?1365982762</fda-label>
  <msds>//s3-us-west-2.amazonaws.com/drugbank/msds/DB06771.pdf?1365982762</msds>
  <patents>
    <patent>
      <number>6685958</number>
      <country>United States</country>
      <approved>2004-02-03</approved>
      <expires>2021-06-20</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>6699492</number>
      <country>United States</country>
      <approved>2004-03-02</approved>
      <expires>2019-03-31</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>5447926</number>
      <country>United States</country>
      <approved>1995-09-05</approved>
      <expires>2012-09-05</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8415342</number>
      <country>United States</country>
      <approved>2013-04-09</approved>
      <expires>2030-11-07</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8937062</number>
      <country>United States</country>
      <approved>2015-01-20</approved>
      <expires>2029-11-13</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8481526</number>
      <country>United States</country>
      <approved>2013-07-09</approved>
      <expires>2031-01-09</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8604020</number>
      <country>United States</country>
      <approved>2013-12-10</approved>
      <expires>2030-03-12</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
  </patents>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB00656</drugbank-id>
      <name>Trazodone</name>
      <description>The risk or severity of QTc prolongation can be increased when Trazodone is combined with Besifloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11642</drugbank-id>
      <name>Pitolisant</name>
      <description>Besifloxacin may increase the QTc-prolonging activities of Pitolisant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12825</drugbank-id>
      <name>Lefamulin</name>
      <description>Lefamulin may increase the QTc-prolonging activities of Besifloxacin.</description>
    </drug-interaction>
  </drug-interactions>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>0.7</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-3.4</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>1.43e-01 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>0.54</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>7-[(3R)-3-aminoazepan-1-yl]-8-chloro-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>besifloxacin</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>393.84</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>393.125547465</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>N[C@@H]1CCCCN(C1)C1=C(F)C=C2C(=O)C(=CN(C3CC3)C2=C1Cl)C(O)=O</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C19H21ClFN3O3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C19H21ClFN3O3/c20-15-16-12(18(25)13(19(26)27)9-24(16)11-4-5-11)7-14(21)17(15)23-6-2-1-3-10(22)8-23/h7,9-11H,1-6,8,22H2,(H,26,27)/t10-/m1/s1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>QFFGVLORLPOAEC-SNVBAGLBSA-N</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>86.87</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>101.75</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>39</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>6</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest acidic)</kind>
      <value>5.64</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>9.67</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>4</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties>
    <property>
      <kind>Water Solubility</kind>
      <value>Not soluble in water </value>
      <source>MSDS </source>
    </property>
    <property>
      <kind>pKa</kind>
      <value>6.0-7.0</value>
      <source>MSDS </source>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>20556</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEBI</resource>
      <identifier>135622</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Compound</resource>
      <identifier>10178705</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>175427091</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Drug</resource>
      <identifier>D08872</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>8354210</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Besifloxacin</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL1201760</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>RxList</resource>
      <url>http://www.rxlist.com/besivance-drug.htm</url>
    </external-link>
    <external-link>
      <resource>Drugs.com</resource>
      <url>http://www.drugs.com/besivance.html</url>
    </external-link>
  </external-links>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target position="1">
      <id>BE0000429</id>
      <name>DNA topoisomerase 4 subunit A</name>
      <organism>Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd)</organism>
      <actions>
        <action>antagonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A17912</ref-id>
            <pubmed-id>20030427</pubmed-id>
            <citation>Carter NJ, Scott LJ: Besifloxacin ophthalmic suspension 0.6%. Drugs. 2010;70(1):83-97. doi: 10.2165/11203820-000000000-00000.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P43702" source="Swiss-Prot">
        <name>DNA topoisomerase 4 subunit A</name>
        <general-function>Dna topoisomerase type ii (atp-hydrolyzing) activity</general-function>
        <specific-function>Topoisomerase IV is essential for chromosome segregation. It relaxes supercoiled DNA. Performs the decatenation events required during the replication of a circular DNA molecule.</specific-function>
        <gene-name>parC</gene-name>
        <locus/>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>6.42</theoretical-pi>
        <molecular-weight>83366.24</molecular-weight>
        <chromosome-location/>
        <organism ncbi-taxonomy-id="71421">Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd)</organism>
        <external-identifiers>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>L42023</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>1574370</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P43702</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>PARC_HAEIN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>5.99.1.3</synonym>
          <synonym>Topoisomerase IV subunit A</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0010299|DNA topoisomerase 4 subunit A
MTNINYEGIEQMPLRTFTEKAYLNYSMYVIMDRALPFIGDGLKPVQRRIVYAMSELGLNA
TAKYKKSARTVGDVLGKFHPHGDSACYEAMVLMAQPFSYRYPLVDGQGNWGAPDDPKSFA
AMRYTESRLSKISEILLNELGQGTVDYQPNFDGTLAEPQYLPARLPHILLNGTTGIAVGM
ATDIPPHNINEIADAAVMLLDNPKAGLDDVLEIVQGPDFPTEAEIISPKSEIRKIYEQGR
GSIKMRATWKKEDGEIIISALPHQSSPSKVIAQIAEQMTAKKLPMLEDIRDEADHENPIR
IVLVPRSNRVDTDALMAHLFATTDLEKSYRVNMNMIGLDHKPAVKGLLEILNEWLDFRRT
TVTRRLQYRLDKVLSRLHILEGLMIAFLNIDEVIEIIRHEDDPKAELMARFNLSDEQADA
ILNLRLRHLAKLEENQLKAEQDELEKERLNLEAILGSERRLNTLIKKEIQEDAKKYANPR
MSQLVEREEAKMISESDMTPAEPVTVILSEMGWVRCAKGHDIDPKSLSYKAGDSYLAHAC
GKSNQAVVFIDSTGRSYALDPLSLPSARSQGEPLTGKLNLPTGATIEYVVMASEQQELLM
ASDAGYGFICKFEDLIARNKAGKALISLPENAKVLKPKTLINSTALVVAITSAGRMLIFP
AQDLPVLSKGKGNKMITIPAANAKDRSELLTKLLLISDQASLEFYSGKRKIVLKPEDLQK
FRAERGRKGSTLPRGLHTNLEIMVIEP</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010300|DNA topoisomerase 4 subunit A (parC)
ATGACAAATATCAACTATGAAGGCATTGAGCAAATGCCTCTACGCACCTTCACTGAAAAG
GCTTATCTCAACTATTCTATGTATGTCATCATGGATCGTGCGTTGCCTTTTATCGGTGAT
GGTTTAAAACCCGTTCAACGTCGTATTGTATATGCGATGTCTGAACTTGGCTTAAATGCC
ACGGCAAAATACAAAAAATCTGCTCGTACCGTCGGTGATGTACTCGGTAAATTCCATCCA
CATGGTGACAGTGCTTGTTATGAAGCTATGGTGTTAATGGCACAACCCTTCTCTTATCGT
TATCCACTTGTAGATGGTCAAGGTAACTGGGGGGCACCAGATGATCCAAAATCCTTCGCA
GCCATGCGTTATACGGAATCTCGCCTATCTAAAATCTCTGAAATCTTGTTGAATGAACTC
GGACAAGGAACAGTAGATTATCAACCAAACTTTGATGGAACCTTGGCTGAACCACAATAT
TTACCTGCTCGTTTACCGCATATTTTATTGAACGGCACAACAGGTATTGCGGTGGGGATG
GCCACAGATATTCCACCACACAATATTAACGAAATTGCTGATGCGGCAGTAATGTTGCTA
GATAATCCTAAAGCGGGATTAGATGATGTACTTGAAATTGTTCAAGGCCCAGATTTTCCA
ACAGAAGCGGAAATTATTTCGCCAAAATCAGAAATTCGTAAAATTTATGAGCAAGGTCGT
GGCTCAATAAAAATGCGTGCAACTTGGAAAAAAGAAGACGGTGAAATTATTATTTCAGCG
CTTCCACATCAATCTTCGCCATCCAAAGTCATTGCACAAATAGCCGAACAAATGACGGCA
AAAAAACTGCCAATGCTAGAAGATATTCGAGATGAAGCCGATCACGAAAATCCAATTCGC
ATTGTGCTAGTTCCTCGCTCAAATCGCGTCGATACTGATGCCTTAATGGCACATTTATTT
GCGACCACAGATCTTGAAAAAAGCTACCGTGTAAATATGAATATGATCGGGCTTGATCAT
AAACCAGCGGTAAAAGGCTTATTAGAAATCTTAAATGAATGGCTTGACTTCCGTCGCACA
ACGGTCACTCGTCGCCTTCAATATCGCCTAGATAAAGTGCTCTCTCGCTTGCATATTTTA
GAAGGCTTGATGATAGCCTTTTTAAATATTGATGAAGTTATCGAAATTATACGCCACGAA
GATGATCCAAAAGCAGAGCTTATGGCACGCTTTAATTTAAGCGATGAACAAGCCGATGCC
ATTTTAAATTTACGCTTACGTCATTTAGCGAAATTAGAAGAAAACCAACTCAAAGCAGAA
CAAGATGAACTTGAAAAAGAGCGGTTAAATTTAGAAGCAATTTTAGGATCAGAACGCCGT
TTGAATACGCTTATCAAAAAAGAAATTCAAGAAGATGCGAAAAAATATGCCAATCCACGT
ATGTCTCAACTGGTCGAACGTGAAGAAGCCAAAATGATCTCTGAAAGTGATATGACACCA
GCAGAACCAGTTACTGTCATCTTATCAGAAATGGGCTGGGTACGTTGTGCAAAAGGACAC
GATATTGATCCTAAATCATTAAGCTACAAAGCTGGTGATAGCTATCTAGCTCACGCTTGT
GGCAAAAGTAATCAAGCCGTTGTATTCATTGATAGCACGGGGCGGAGTTATGCACTCGAT
CCGCTTTCCTTGCCTTCCGCTCGCTCCCAAGGCGAACCACTTACAGGTAAACTCAATTTA
CCCACTGGTGCGACCATTGAATATGTTGTAATGGCCAGCGAACAGCAAGAATTATTGATG
GCTTCTGATGCAGGATATGGTTTTATTTGTAAATTTGAAGATTTAATTGCACGTAACAAG
GCTGGAAAAGCCTTGATTTCTTTACCAGAAAATGCCAAAGTGTTGAAGCCTAAAACATTG
ATAAATTCTACCGCACTTGTTGTCGCAATCACATCAGCAGGCAGAATGTTGATTTTTCCA
GCACAGGATTTACCGGTATTATCAAAAGGTAAAGGCAATAAAATGATCACTATTCCCGCA
GCGAATGCAAAAGATCGTAGCGAACTATTGACAAAATTATTGCTTATTTCAGATCAAGCA
AGTCTTGAATTTTATTCTGGAAAACGAAAAATTGTATTAAAACCAGAAGATCTGCAAAAG
TTCCGCGCAGAACGAGGCAGAAAAGGTTCGACATTACCACGTGGATTACATACCAATCTT
GAAATTATGGTAATCGAGCCGTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF03989</identifier>
            <name>DNA_gyraseA_C</name>
          </pfam>
          <pfam>
            <identifier>PF00521</identifier>
            <name>DNA_topoisoIV</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>chromosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extrinsic component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ATP binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>DNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>DNA topoisomerase type II (ATP-hydrolyzing) activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>chromosome segregation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>DNA topological change</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="2">
      <id>BE0003726</id>
      <name>DNA topoisomerase 4 subunit A</name>
      <organism>Streptococcus pneumoniae serotype 4 (strain ATCC BAA-334 / TIGR4)</organism>
      <actions>
        <action>antagonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A17912</ref-id>
            <pubmed-id>20030427</pubmed-id>
            <citation>Carter NJ, Scott LJ: Besifloxacin ophthalmic suspension 0.6%. Drugs. 2010;70(1):83-97. doi: 10.2165/11203820-000000000-00000.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P72525" source="Swiss-Prot">
        <name>DNA topoisomerase 4 subunit A</name>
        <general-function>Dna topoisomerase type ii (atp-hydrolyzing) activity</general-function>
        <specific-function>Topoisomerase IV is essential for chromosome segregation. It relaxes supercoiled DNA. Performs the decatenation events required during the replication of a circular DNA molecule.</specific-function>
        <gene-name>parC</gene-name>
        <locus/>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>5.35</theoretical-pi>
        <molecular-weight>93132.2</molecular-weight>
        <chromosome-location/>
        <organism ncbi-taxonomy-id="170187">Streptococcus pneumoniae serotype 4 (strain ATCC BAA-334 / TIGR4)</organism>
        <external-identifiers>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>Z67739</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>1490399</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P72525</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>PARC_STRPN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>5.99.1.3</synonym>
          <synonym>Topoisomerase IV subunit A</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0017200|DNA topoisomerase 4 subunit A
MSNIQNMSLEDIMGERFGRYSKYIIQDRALPDIRDGLKPVQRRILYSMNKDSNTFDKSYR
KSAKSVGNIMGNFHPHGDSSIYDAMVRMSQNWKNREILVEMHGNNGSMDGDPPAAMRYTE
ARLSEIAGYLLQDIEKKTVPFAWNFDDTEKEPTVLPAAFPNLLVNGSTGISAGYATDIPP
HNLAEVIDAAVYMIDHPTAKIDKLMEFLPGPDFPTGAIIQGRDEIKKAYETGKGRVVVRS
KTEIEKLKGGKEQIVIIEIPYEINKANLVKKIDDVRVNNKVAGIAEVRDESDRDGLRIAI
ELKKDANTELVLNYLFKYTDLQINYNFNMVAIDNFTPRQVGIVPILSSYIAHRREVILAR
SRFDKEKAEKRLHIVEGLIRVISILDEVIALIRASENKADAKENLKVSYDFTEEQAEAIV
TLQLYRLTNTDVVVLQEEEAELREKIAMLAAIIGDERTMYNLMKKELREVKKKFATPRLS
SLEDTAKAIEIDTASLIAEEDTYVSVTKAGYIKRTSPRSFAASTLEEIGKRDDDRLIFVQ
SAKTTQHLLMFTSLGNVIYRPIHELADIRWKDIGEHLSQTITNFETNEEILYVEVLDQFD
DATTYFAVTRLGQIKRVERKEFTPWRTYRSKSVKYAKLKDDTDQIVAVAPIKLDDVVLVS
QNGYALRFNIEEVPVVGAKAAGVKAMNLKEDDVLQSGFICNTSSFYLLTQRGSLKRVSIE
EILATSRAKRGLQVLRELKNKPHRVFLAGAVAEQGFVGDFFSTEVDVNDQTLLVQSNKGT
IYESRLQDLNLSERTSNGSFISDTISDEEVFDAYLQEVVTEDK</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0017201|DNA topoisomerase 4 subunit A (parC)
ATGTCTAACATTCAAAACATGTCCCTGGAGGACATCATGGGAGAGCGCTTTGGTCGCTAC
TCCAAGTACATTATTCAAGACCGGGCTTTGCCAGATATTCGTGATGGGTTGAAGCCGGTT
CAGCGCCGTATTCTTTATTCTATGAATAAGGATAGCAATACTTTTGACAAGAGCTACCGT
AAGTCGGCCAAGTCAGTCGGGAACATCATGGGGAATTTCCACCCACACGGGGATTCTTCT
ATCTATGATGCCATGGTTCGTATGTCACAGAACTGGAAAAATCGTGAGATTCTAGTTGAA
ATGCACGGTAATAACGGTTCTATGGACGGAGATCCTCCTGCGGCTATGCGTTATACTGAG
GCACGTTTGTCTGAAATTGCAGGCTACCTTCTTCAGGATATCGAGAAAAAGACAGTTCCT
TTTGCATGGAACTTTGACGATACGGAGAAAGAACCAACGGTCTTGCCAGCAGCCTTTCCA
AACCTCTTGGTCAATGGTTCGACTGGGATTTCGGCTGGTTATGCCACAGACATTCCTCCC
CATAATTTAGCTGAGGTCATAGATGCTGCAGTTTACATGATTGACCACCCAACTGCAAAG
ATTGATAAACTCATGGAATTCTTGCCTGGACCAGACTTCCCTACAGGGGCTATTATTCAG
GGTCGTGATGAAATCAAGAAAGCTTATGAGACTGGGAAAGGGCGCGTGGTTGTTCGTTCC
AAGACTGAAATTGAAAAGCTAAAAGGTGGTAAGGAACAAATCGTTATTATTGAGATTCCT
TATGAAATCAATAAGGCCAATCTAGTCAAGAAAATCGATGATGTTCGTGTTAATAACAAG
GTAGCTGGGATTGCTGAGGTTCGTGATGAGTCTGACCGTGATGGTCTTCGTATCGCTATC
GAACTTAAGAAAGACGCTAATACTGAGCTTGTTCTCAACTACTTATTTAAGTACACCGAC
CTACAAATCAACTACAACTTTAATATGGTGGCGATTGACAATTTCACACCTCGTCAGGTT
GGGATTGTTCCAATCCTGTCTAGCTATATCGCTCACCGTCGAGAAGTGATTTTGGCGCGT
TCACGCTTTGACAAAGAAAAGGCTGAGAAACGTCTCCATATCGTCGAAGGTTTGATTCGT
GTGATTTCGATTTTGGATGAAGTCATTGCTCTTATCCGTGCTTCTGAGAATAAGGCGGAC
GCCAAGGAAAACCTCAAAGTTAGCTATGATTTTACGGAAGAACAGGCTGAGGCTATCGTA
ACTTTGCAACTGTACCGTTTGACCAATACCGATGTGGTTGTCTTGCAGGAAGAAGAAGCA
GAGCTTCGTGAGAAGATTGCTATGCTGGCGGCTATTATCGGTGATGAAAGGACTATGTAC
AATCTCATGAAGAAAGAACTTCGTGAGGTCAAGAAGAAATTTGCAACTCCTCGTTTGAGT
TCTTTAGAAGACACTGCGAAAGCAATTGAGATTGATACAGCTAGTCTTATCGCTGAGGAA
GATACCTACGTCAGCGTGACCAAGGCAGGTTACATCAAGCGTACCAGTCCACGTTCCTTT
GCGGCTTCCACCTTGGAAGAAATTGGCAAGCGTGATGATGACCGTTTGATTTTTGTTCAA
TCTGCCAAGACAACCCAGCACCTCTTGATGTTCACAAGTCTTGGAAATGTCATCTACAGA
CCAATCCATGAGTTGGCAGATATTCGTTGGAAGGACATCGGAGAGCATCTGAGCCAAACC
ATCACAAACTTTGAAACGAATGAAGAAATCCTTTATGTGGAAGTACTGGATCAGTTTGAC
GATGCGACAACCTACTTTGCAGTGACTCGCCTTGGTCAAATCAAACGGGTAGAGCGAAAA
GAATTCACTCCATGGCGGACCTATAGATCTAAGTCTGTCAAGTATGCTAAGCTCAAAGAC
GATACAGATCAGATTGTAGCAGTGGCTCCGATTAAACTAGATGATGTTGTCTTGGTTAGT
CAAAATGGTTATGCCCTGCGTTTCAATATCGAAGAGGTTCCGGTTGTCGGTGCTAAGGCA
GCAGGTGTCAAGGCTATGAATTTGAAAGAAGATGATGTCCTCCAATCTGGCTTTATCTGT
AATACTTCGTCCTTCTACCTCTTGACCCAGCGTGGAAGCTTGAAACGTGTTTCCATTGAG
GAAATTCTAGCAACCAGCCGTGCCAAACGAGGATTACAAGTCTTGCGTGAGTTGAAAAAC
AAACCGCATCGTGTCTTCTTGGCAGGAGCAGTTGCAGAGCAAGGATTTGTTGGCGATTTC
TTCAGTACGGAAGTGGATGTGAACGACCAAACTCTGCTTGTCCAATCCAATAAAGGAACA
ATCTATGAAAGCCGATTGCAAGACTTGAACTTGTCAGAACGCACTAGCAATGGAAGCTTC
ATTTCTGACACGATTTCAGATGAAGAAGTTTTTGACGCTTATCTTCAGGAAGTAGTTACT
GAAGATAAATAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF03989</identifier>
            <name>DNA_gyraseA_C</name>
          </pfam>
          <pfam>
            <identifier>PF00521</identifier>
            <name>DNA_topoisoIV</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>chromosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extrinsic component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ATP binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>DNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>DNA topoisomerase type II (ATP-hydrolyzing) activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>chromosome segregation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>DNA topological change</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="3">
      <id>BE0000366</id>
      <name>DNA gyrase subunit A</name>
      <organism>Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd)</organism>
      <actions>
        <action>antagonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A17912</ref-id>
            <pubmed-id>20030427</pubmed-id>
            <citation>Carter NJ, Scott LJ: Besifloxacin ophthalmic suspension 0.6%. Drugs. 2010;70(1):83-97. doi: 10.2165/11203820-000000000-00000.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P43700" source="Swiss-Prot">
        <name>DNA gyrase subunit A</name>
        <general-function>Dna topoisomerase type ii (atp-hydrolyzing) activity</general-function>
        <specific-function>DNA gyrase negatively supercoils closed circular double-stranded DNA in an ATP-dependent manner and also catalyzes the interconversion of other topological isomers of double-stranded DNA rings, including catenanes and knotted rings.</specific-function>
        <gene-name>gyrA</gene-name>
        <locus/>
        <cellular-location>Cytoplasm</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>4.85</theoretical-pi>
        <molecular-weight>97817.145</molecular-weight>
        <chromosome-location/>
        <organism ncbi-taxonomy-id="71421">Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd)</organism>
        <external-identifiers>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>L42023</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>1574722</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P43700</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>GYRA_HAEIN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>5.99.1.3</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0010114|DNA gyrase subunit A
MTDSIQSSITPVNIEEELKSSYLDYAMSVIVGRALPDVRDGLKPVHRRVLFSMDREGNTA
NKKYVKSARVVGDVIGKYHPHGDSAVYDTIVRMAQPFSLRYMLVDGQGNFGSIDGDAPAA
MRYTEVRMQKITQALLTDLDKETVNFSPNYDGELMIPDVLPTRIPALLANGSSGIAVGMA
TNIPPHNLNEVLNGCLAYIDKNEITIDELMQHIPGPDFPTAALINGRKGIEEAYRTGRGK
VYVRARATVETNEKGREQIIVSELPYQVNKAKLVEKIAELIREKKIEGISNITDLSNKEG
IRIEIDIKRDAVGEVVLNHLYSLTQMQVTFGINMVALDHGQPRLFNLKEIIEAFVLHRRE
VVTRRSIFELRKARERTHILEGLAVARSNIDEMIAIIRNSKNREEAATSISSRSWTLHSD
IINLLDASARPDELEENLGIQGEQYYLSPAQVNAILELRLHRLTGIAFEEVIKEYEELLV
KIADLLHILSSAERLMEVIREELEEVKAQFGDDRLTEITAASGDIDLEDLIAQEDVVVTL
SHEGYVKYQPLTDYEAQRRGGKGKSATKMKEEDFIEKLLVANTHDTILCFSSRGRLYWLK
VYQLPQASRGARGRPIVNILPLQENERITAILPVSAYEEDKFVVMATAGGIVKKIALTEF
SRPRSNGIIALNLRDEDELIGVDITDGSNEIMLFSSQGRVVRFAENAVRAMGRLATGVRG
IKLALTNDISDDESAVEIEDISDDNAEASLDLNIDKVVSLVVPKGEGAILTATQNGYGKR
TQLSEYPTKSRNTKGVISIKVSERNGKVVAATQVEETDQIMLITDAGTLVRTRVSEVSIV
GRNTQGVRLIRTADDEHVVSLERVCDADEDDSLEESSSEE</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010115|DNA gyrase subunit A (gyrA)
ATGACGGATTCAATCCAATCATCTATCACCCCTGTCAATATCGAAGAAGAACTTAAATCT
TCCTACCTTGACTACGCGATGTCGGTTATCGTTGGGCGTGCATTACCTGACGTTCGAGAT
GGTTTAAAACCTGTTCACCGCCGCGTACTATTCTCAATGGATCGCGAAGGCAATACCGCC
AATAAAAAATACGTAAAATCAGCGCGTGTTGTGGGTGATGTAATCGGTAAATATCACCCG
CATGGTGACTCCGCCGTGTACGATACCATCGTTCGTATGGCACAACCCTTCTCACTTCGC
TATATGTTGGTTGATGGGCAAGGTAACTTTGGTTCAATTGATGGTGATGCGCCAGCTGCA
ATGCGTTATACCGAAGTACGTATGCAAAAAATTACGCAAGCATTGCTCACGGATTTGGAT
AAAGAAACCGTCAATTTCTCGCCAAACTATGATGGCGAATTAATGATTCCAGATGTATTG
CCGACTCGTATTCCAGCACTGTTAGCAAATGGTTCTTCTGGTATTGCGGTGGGGATGGCA
ACTAACATTCCCCCTCACAACTTAAACGAAGTATTAAATGGTTGTTTGGCTTATATTGAC
AAAAATGAAATTACCATTGATGAATTAATGCAACATATTCCAGGGCCTGACTTCCCAACG
GCTGCGTTAATTAATGGTCGTAAAGGGATTGAAGAGGCCTATCGCACTGGTCGTGGTAAA
GTGTATGTTCGTGCTCGTGCAACGGTAGAAACCAACGAAAAAGGACGCGAGCAAATTATC
GTGTCTGAATTGCCATACCAAGTAAATAAAGCAAAATTAGTCGAGAAAATCGCCGAATTA
ATTCGCGAGAAAAAAATCGAAGGTATCAGCAATATTACTGACCTTTCAAATAAAGAAGGG
ATCCGTATTGAAATTGATATTAAACGTGATGCAGTGGGGGAAGTGGTATTAAACCATCTT
TACTCACTCACTCAAATGCAAGTGACCTTTGGTATCAATATGGTGGCATTGGATCACGGT
CAGCCACGTTTATTTAATCTTAAAGAAATTATTGAAGCCTTTGTTTTACACCGCCGTGAA
GTGGTTACACGTCGTTCTATCTTTGAGCTTCGCAAAGCACGTGAACGTACGCATATTTTG
GAAGGTTTAGCGGTTGCTCGTTCTAATATCGATGAAATGATTGCGATCATTCGTAACTCT
AAAAACCGTGAAGAAGCCGCAACATCAATCAGTTCACGCTCTTGGACGTTACATAGCGAT
ATTATTAATCTTCTTGATGCTTCTGCTCGTCCTGATGAGTTAGAAGAAAATCTTGGTATT
CAAGGCGAACAATATTACTTATCGCCAGCGCAAGTAAACGCAATTCTAGAACTTCGCTTA
CACCGTTTAACGGGCATTGCGTTTGAAGAAGTTATAAAAGAATATGAAGAATTATTAGTT
AAAATTGCGGATCTTCTTCATATTTTAAGTAGTGCAGAACGTTTAATGGAAGTAATTCGT
GAAGAATTGGAAGAAGTAAAAGCACAATTTGGTGATGATCGTTTAACTGAAATTACCGCT
GCTTCTGGCGATATTGATTTAGAAGATTTAATCGCACAAGAAGACGTGGTTGTGACGCTT
TCTCACGAAGGTTATGTGAAATACCAACCACTGACTGACTATGAAGCACAACGCCGTGGC
GGTAAAGGCAAATCTGCAACGAAGATGAAAGAAGAAGATTTCATCGAAAAATTACTGGTA
GCAAATACTCACGATACCATCCTCTGCTTCTCTAGCCGTGGTCGTTTATATTGGTTGAAA
GTATATCAACTTCCGCAAGCGAGCCGTGGCGCACGCGGTCGTCCAATTGTGAATATTCTT
CCGTTACAAGAAAACGAACGTATTACTGCAATCTTGCCAGTTTCTGCTTACGAAGAAGAT
AAATTCGTAGTCATGGCAACTGCTGGCGGTATTGTGAAGAAAATCGCCTTAACCGAATTT
AGCCGTCCACGTTCAAACGGTATCATCGCATTGAATTTACGTGACGAAGATGAATTAATC
GGCGTGGATATTACTGATGGCAGCAACGAAATTATGTTGTTCTCATCACAAGGTCGCGTG
GTGCGTTTTGCTGAAAATGCCGTGCGTGCGATGGGGCGTTTAGCAACAGGTGTTCGCGGT
ATCAAACTGGCTTTAACAAACGATATTTCTGACGATGAAAGTGCGGTAGAAATTGAAGAT
ATTTCTGATGACAACGCTGAAGCATCATTAGACTTAAATATCGATAAAGTGGTCTCGCTC
GTTGTGCCAAAAGGTGAAGGGGCAATTTTAACCGCAACGCAAAACGGCTACGGAAAACGC
ACACAATTAAGTGAATACCCAACTAAATCACGTAATACAAAAGGTGTGATTTCGATTAAA
GTGAGTGAACGCAATGGTAAAGTCGTTGCCGCAACTCAAGTAGAAGAAACAGACCAAATT
ATGTTGATCACTGATGCAGGAACCCTTGTTCGCACACGCGTAAGCGAAGTGAGCATTGTA
GGGCGTAACACGCAAGGTGTTCGCTTAATTCGTACTGCCGATGATGAACACGTAGTAAGT
TTAGAACGTGTTTGTGATGCAGATGAAGATGATTCTTTGGAAGAAAGCAGTTCTGAAGAA
TAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF03989</identifier>
            <name>DNA_gyraseA_C</name>
          </pfam>
          <pfam>
            <identifier>PF00521</identifier>
            <name>DNA_topoisoIV</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>chromosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ATP binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>DNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>DNA topoisomerase type II (ATP-hydrolyzing) activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>DNA topological change</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>DNA-dependent DNA replication</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="4">
      <id>BE0003724</id>
      <name>DNA gyrase subunit A</name>
      <organism>Streptococcus pneumoniae serotype 4 (strain ATCC BAA-334 / TIGR4)</organism>
      <actions>
        <action>antagonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A17912</ref-id>
            <pubmed-id>20030427</pubmed-id>
            <citation>Carter NJ, Scott LJ: Besifloxacin ophthalmic suspension 0.6%. Drugs. 2010;70(1):83-97. doi: 10.2165/11203820-000000000-00000.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P72524" source="Swiss-Prot">
        <name>DNA gyrase subunit A</name>
        <general-function>Dna topoisomerase type ii (atp-hydrolyzing) activity</general-function>
        <specific-function>DNA gyrase negatively supercoils closed circular double-stranded DNA in an ATP-dependent manner and also catalyzes the interconversion of other topological isomers of double-stranded DNA rings, including catenanes and knotted rings.</specific-function>
        <gene-name>gyrA</gene-name>
        <locus/>
        <cellular-location>Cytoplasm</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>6.07</theoretical-pi>
        <molecular-weight>92052.595</molecular-weight>
        <chromosome-location/>
        <organism ncbi-taxonomy-id="170187">Streptococcus pneumoniae serotype 4 (strain ATCC BAA-334 / TIGR4)</organism>
        <external-identifiers>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>AE005672</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>14971465</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P72524</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>GYRA_STRPN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>5.99.1.3</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0017204|DNA gyrase subunit A
MQDKNLVNVNLTKEMKASFIDYAMSVIVARALPDVRDGLKPVHRRILYGMNELGVTPDKP
HKKSARITGDVMGKYHPHGDSSIYEAMVRMAQWWSYRYMLVDGHGNFGSMDGDSAAAQRY
TEARMSKIALEMLRDINKNTVDFVDNYDANEREPLVLPARFPNLLVNGATGIAVGMATNI
PPHNLGETIDAVKLVMDNPEVTTKDLMEVLPGPDFPTGALVMGKSGIHKAYETGKGSIVL
RSRTEIETTKTGRERIVVTEFPYMVNKTKVHEHIVRLVQEKRIEGITAVRDESNREGVRF
VIEVKRDASANVILNNLFKMTQMQTNFGFNMLAIQNGIPKILSLRQILDAYIEHQKEVVV
RRTRFDKEKAEARAHILEGLLIALDHIDEVIRIIRASETDAEAQAELMSKFKLSERQSQA
ILDMRLRRLTGLERDKIQSEYDDLLALIADLADILAKPERVSQIIKDELDEVKRKFSDKR
RTELMIGQVLSLEDEDLIEESDVLITLSNRGYIKRLDQDEFTAQKRGGRGVQGTGVKDDD
FVRELVSTSTHDHLLFFTNKGRVYRLKGYEIPEYGRTAKGLPVVNLLKLDEDESIQTVIN
VESDRSDDAYLFFTTRHGIVKRTSVKEFANIRQNGLKALNLKDEDELINVLLAEGDMDII
IGTKFGYAVRFNQSAVRGMSRIATGVKGVNLREGDTVVGASLITDQDEVLIITEKGYGKR
TVATEYPTKGRGGKGMQTAKITEKNGLLAGLMTVQGDEDLMIITDTGVMIRTNLANISQT
GRATMGVKVMRLDQDAQIVTFTTVAVAEKEEVGTENETEGEA</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0017205|DNA gyrase subunit A (gyrA)
ATGCAGGATAAAAATTTAGTGAATGTCAATCTGACAAAGGAGATGAAGGCAAGTTTTATC
GACTACGCCATGAGTGTTATCGTAGCGCGAGCTCTTCCTGATGTTCGAGATGGCTTAAAA
CCTGTTCACCGTCGCATTCTCTACGGAATGAATGAATTGGGTGTGACCCCAGACAAACCC
CATAAAAAATCTGCTCGTATTACAGGGGATGTCATGGGTAAATATCACCCACACGGGGAT
TCCTCTATTTATGAAGCCATGGTCCGTATGGCTCAATGGTGGAGCTACCGTTACATGCTT
GTAGATGGTCATGGGAATTTTGGTTCCATGGATGGAGATAGTGCTGCCGCTCAACGTTAT
ACCGAGGCACGTATGAGCAAGATTGCTCTGGAAATGCTTCGTGATATCAACAAAAATACA
GTTGATTTCGTTGATAACTATGATGCCAATGAACGGGAACCCTTGGTCTTGCCAGCGCGT
TTTCCAAACCTTTTGGTTAATGGAGCAACTGGTATCGCGGTTGGGATGGCAACCAATATT
CCACCTCATAATCTGGGTGAAACCATTGATGCAGTGAAGTTGGTCATGGATAATCCTGAA
GTGACTACCAAGGACTTGATGGAAGTCTTGCCTGGACCAGATTTTCCAACTGGTGCTCTT
GTCATGGGGAAATCAGGTATCCATAAGGCTTATGAAACAGGTAAAGGTTCGATTGTCCTA
CGTTCTCGTACAGAGATTGAAACGACTAAGACTGGTCGTGAGCGTATCGTTGTAACAGAA
TTTCCTTACATGGTCAATAAAACCAAGGTGCATGAGCATATTGTTCGCTTGGTTCAGGAA
AAACGCATTGAGGGTATCACAGCAGTACGTGATGAGTCAAACCGTGAAGGTGTTCGATTT
GTTATTGAAGTCAAGCGCGACGCCTCAGCCAATGTTATTCTCAATAACCTCTTCAAAATG
ACCCAAATGCAAACCAATTTTGGTTTCAATATGCTCGCTATCCAAAATGGTATACCGAAA
ATTTTGTCTCTTCGTCAGATTTTGGATGCTTATATCGAGCACCAAAAAGAAGTGGTTGTT
CGTCGTACACGTTTTGATAAGGAAAAAGCGGAAGCGCGCGCTCATATCTTAGAAGGTCTC
TTGATTGCGCTAGACCATATCGACGAAGTGATTCGTATCATCCGTGCTAGTGAAACGGAT
GCGGAAGCTCAAGCTGAGTTGATGAGCAAGTTTAAGCTTTCTGAACGTCAAAGTCAAGCT
ATCCTTGATATGCGTCTTCGTCGTTTGACAGGTTTGGAACGCGATAAGATTCAATCTGAG
TATGATGACCTCTTGGCTCTGATTGCGGATTTAGCAGATATTCTTGCTAAGCCTGAACGT
GTTTCTCAAATTATCAAAGACGAATTGGATGAAGTTAAACGTAAATTTTCTGATAAGCGC
CGTACAGAGTTGATGATTGGACAGGTCTTGAGTCTCGAGGATGAGGACTTGATTGAAGAA
TCGGATGTCTTGATTACCCTTTCTAACAGAGGCTACATTAAGCGTTTGGATCAGGACGAG
TTCACTGCTCAAAAACGTGGGGGTCGTGGTGTCCAAGGAACGGGAGTGAAAGATGATGAC
TTTGTTCGTGAGTTAGTGTCAACTAGCACCCATGATCATCTGCTCTTCTTCACAAACAAG
GGACGTGTCTATCGTCTTAAAGGTTATGAAATTCCTGAGTATGGTCGGACTGCCAAAGGG
CTACCAGTAGTCAATCTCTTGAAATTGGATGAAGACGAAAGTATTCAGACGGTTATCAAT
GTTGAGTCTGATCGCAGTGATGATGCTTATCTCTTCTTTACAACCCGTCACGGTATTGTG
AAGAGAACCAGTGTTAAGGAGTTTGCCAATATTCGTCAAAATGGTCTCAAAGCGCTGAAT
TTAAAGGATGAAGATGAGTTAATCAATGTCTTGTTGGCAGAAGGAGATATGGATATTATC
ATTGGTACCAAGTTTGGTTATGCAGTTCGCTTTAATCAATCAGCCGTTCGTGGTATGAGC
CGTATCGCCACTGGTGTGAAAGGTGTTAACCTTCGTGAAGGAGACACAGTTGTTGGTGCC
AGCTTGATTACTGATCAAGATGAGGTTCTTATTATCACAGAAAAAGGATATGGTAAGCGT
ACAGTCGCTACTGAATACCCAACAAAAGGTCGTGGTGGTAAGGGAATGCAGACAGCTAAA
ATTACCGAAAAAAATGGCTTGCTGGCCGGTCTTATGACTGTTCAAGGGGATGAGGATTTG
ATGATTATCACTGATACAGGTGTCATGATTCGAACCAATCTTGCCAATATTTCACAAACA
GGACGTGCAACTATGGGAGTTAAAGTAATGCGCCTGGATCAAGATGCTCAGATAGTGACT
TTCACAACGGTTGCGGTGGCAGAAAAAGAAGAAGTTGGGACAGAAAACGAAACAGAAGGT
GAAGCATAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF03989</identifier>
            <name>DNA_gyraseA_C</name>
          </pfam>
          <pfam>
            <identifier>PF00521</identifier>
            <name>DNA_topoisoIV</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>chromosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ATP binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>DNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>DNA topoisomerase type II (ATP-hydrolyzing) activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>DNA topological change</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>DNA-dependent DNA replication</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
  </targets>
  <enzymes>
    <enzyme position="5">
      <id>BE0002433</id>
      <name>Cytochrome P450 1A2</name>
      <organism>Humans</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A39085</ref-id>
            <pubmed-id>19026171</pubmed-id>
            <citation>Zhang L, Wei MJ, Zhao CY, Qi HM: Determination of the inhibitory potential of 6 fluoroquinolones on CYP1A2 and CYP2C9 in human liver microsomes. Acta Pharmacol Sin. 2008 Dec;29(12):1507-14. doi: 10.1111/j.1745-7254.2008.00908.x.</citation>
          </article>
          <article>
            <ref-id>A38542</ref-id>
            <pubmed-id>21190921</pubmed-id>
            <citation>Shahzadi A, Javed I, Aslam B, Muhammad F, Asi MR, Ashraf MY, Zia-ur-Rahman: Therapeutic effects of ciprofloxacin on the pharmacokinetics of carbamazepine in healthy adult male volunteers. Pak J Pharm Sci. 2011 Jan;24(1):63-8.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>no</known-action>
      <polypeptide id="P05177" source="Swiss-Prot">
        <name>Cytochrome P450 1A2</name>
        <general-function>Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen</general-function>
        <specific-function>Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N3-demethylation. Also acts in the metabolism of aflatoxin B1 and acetaminophen. Participates in the bioactivation of carcinogenic aromatic and heterocyclic amines. Catalizes the N-hydroxylation of heterocyclic amines and the O-deethylation of phenacetin.</specific-function>
        <gene-name>CYP1A2</gene-name>
        <locus>15q24</locus>
        <cellular-location>Endoplasmic reticulum membrane</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>9.43</theoretical-pi>
        <molecular-weight>58293.76</molecular-weight>
        <chromosome-location>15</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:2596</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>CYP1A2</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>Z00036</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1319</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P05177</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>CP1A2_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>1.14.14.1</synonym>
          <synonym>Cholesterol 25-hydroxylase</synonym>
          <synonym>CYPIA2</synonym>
          <synonym>Cytochrome P(3)450</synonym>
          <synonym>Cytochrome P450 4</synonym>
          <synonym>Cytochrome P450-P3</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0004778|Cytochrome P450 1A2
MALSQSVPFSATELLLASAIFCLVFWVLKGLRPRVPKGLKSPPEPWGWPLLGHVLTLGKN
PHLALSRMSQRYGDVLQIRIGSTPVLVLSRLDTIRQALVRQGDDFKGRPDLYTSTLITDG
QSLTFSTDSGPVWAARRRLAQNALNTFSIASDPASSSSCYLEEHVSKEAKALISRLQELM
AGPGHFDPYNQVVVSVANVIGAMCFGQHFPESSDEMLSLVKNTHEFVETASSGNPLDFFP
ILRYLPNPALQRFKAFNQRFLWFLQKTVQEHYQDFDKNSVRDITGALFKHSKKGPRASGN
LIPQEKIVNLVNDIFGAGFDTVTTAISWSLMYLVTKPEIQRKIQKELDTVIGRERRPRLS
DRPQLPYLEAFILETFRHSSFLPFTIPHSTTRDTTLNGFYIPKKCCVFVNQWQVNHDPEL
WEDPSEFRPERFLTADGTAINKPLSEKMMLFGMGKRRCIGEVLAKWEIFLFLAILLQQLE
FSVPPGVKVDLTPIYGLTMKHARCEHVQARRFSIN</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0011742|Cytochrome P450 1A2 (CYP1A2)
ATGGCATTGTCCCAGTCTGTTCCCTTCTCGGCCACAGAGCTTCTCCTGGCCTCTGCCATC
TTCTGCCTGGTATTCTGGGTGCTCAAGGGTTTGAGGCCTCGGGTCCCCAAAGGCCTGAAA
AGTCCACCAGAGCCATGGGGCTGGCCCTTGCTCGGGCATGTGCTGACCCTGGGGAAGAAC
CCGCACCTGGCACTGTCAAGGATGAGCCAGCGCTACGGGGACGTCCTGCAGATCCGCATT
GGCTCCACGCCCGTGCTGGTGCTGAGCCGCCTGGACACCATCCGGCAGGCCCTGGTGCGG
CAGGGCGACGATTTCAAGGGCCGGCCTGACCTCTACACCTCCACCCTCATCACTGATGGC
CAGAGCTTGACCTTCAGCACAGACTCTGGACCGGTGTGGGCTGCCCGCCGGCGCCTGGCC
CAGAATGCCCTCAACACCTTCTCCATCGCCTCTGACCCAGCTTCCTCATCCTCCTGCTAC
CTGGAGGAGCATGTGAGCAAGGAGGCTAAGGCCCTGATCAGCAGGTTGCAGGAGCTGATG
GCAGGGCCTGGGCACTTCGACCCTTACAATCAGGTGGTGGTGTCAGTGGCCAACGTCATT
GGTGCCATGTGCTTCGGACAGCACTTCCCTGAGAGTAGCGATGAGATGCTCAGCCTCGTG
AAGAACACTCATGAGTTCGTGGAGACTGCCTCCTCCGGGAACCCCCTGGACTTCTTCCCC
ATCCTTCGCTACCTGCCTAACCCTGCCCTGCAGAGGTTCAAGGCCTTCAACCAGAGGTTC
CTGTGGTTCCTGCAGAAAACAGTCCAGGAGCACTATCAGGACTTTGACAAGAACAGTGTC
CGGGACATCACGGGTGCCCTGTTCAAGCACAGCAAGAAGGGGCCTAGAGCCAGCGGCAAC
CTCATCCCACAGGAGAAGATTGTCAACCTTGTCAATGACATCTTTGGAGCAGGATTTGAC
ACAGTCACCACAGCCATCTCCTGGAGCCTCATGTACCTTGTGACCAAGCCTGAGATACAG
AGGAAGATCCAGAAGGAGCTGGACACTGTGATTGGCAGGGAGCGGCGGCCCCGGCTCTCT
GACAGACCCCAGCTGCCCTACTTGGAGGCCTTCATCCTGGAGACCTTCCGACACTCCTCC
TTCTTGCCCTTCACCATCCCCCACAGCACAACAAGGGACACAACGCTGAATGGCTTCTAC
ATCCCCAAGAAATGCTGTGTCTTCGTAAACCAGTGGCAGGTCAACCATGACCCAGAGCTG
TGGGAGGACCCCTCTGAGTTCCGGCCTGAGCGGTTCCTCACCGCCGATGGCACTGCCATT
AACAAGCCCTTGAGTGAGAAGATGATGCTGTTTGGCATGGGCAAGCGCCGGTGTATCGGG
GAAGTCCTGGCCAAGTGGGAGATCTTCCTCTTCCTGGCCATCCTGCTACAGCAACTGGAG
TTCAGCGTGCCGCCGGGCGTGAAAGTCGACCTGACCCCCATCTACGGGCTGACCATGAAG
CACGCCCGCTGTGAACATGTCCAGGCGCGGCTGCGCTTCTCCATCAATTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00067</identifier>
            <name>p450</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>intracellular membrane-bounded organelle</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>aromatase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>caffeine oxidase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>demethylase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>electron carrier activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>enzyme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>heme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>iron ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxidoreductase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>alkaloid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>arachidonic acid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular respiration</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to cadmium ion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>dibenzo-p-dioxin metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>drug catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>drug metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>epoxygenase P450 pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>exogenous drug catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>heterocycle metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>hydrogen peroxide biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>lung development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>methylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>monocarboxylic acid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>monoterpenoid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>omega-hydroxylase P450 pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>oxidation-reduction process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>oxidative deethylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>oxidative demethylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>porphyrin-containing compound metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>post-embryonic development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of gene expression</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to estradiol</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to immobilization stress</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to lipopolysaccharide</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>steroid catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>toxin biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>xenobiotic metabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <inhibition-strength>unknown</inhibition-strength>
      <induction-strength/>
    </enzyme>
  </enzymes>
  <carriers/>
  <transporters/>
</drug>